| Name | Title | Contact Details |
|---|
Integrated Health Plan Inc is a Saint Petersburg, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
At Transitions Optical we help people live more vibrant lives by enhancing their vision and the way they perceive light. We were the first to successfully commercialise a plastic photochromic lens in 1990 and our talented people continue to make significant advances in colour science and lens materials, creating a better photochromic experience that`s available to more people. Through our partnerships with optical industry leaders, we offer adaptive solutions in the widest selection of designs and materials, covering hundreds of lens combinations. Our industry leading eyeglass brands are well known; Transitions® Signature®, Transitions® Vantage® and Transitions® XTRActive®. And we don`t stop there; we also make adaptive sunwear and motorcycle helmet shields. Transitions Optical is part of the Essilor Group.
Nuna partners with government, employers, and health plans to improve quality of care.
TytoCare Ltd. is a consumer-focused telehealth company, offering state-of-the-art, patented devices and platform that empower anyone, anywhere and anytime to perform a variety of medical examinations and seamlessly consult with a clinician. The company was founded by Dedi Gilad, Ofer Tzadik and industry experts in 2012. Investors include OrbiMed Advisors, Walgreens, Cambia Health Solutions, Fosun Pharma, LionBird, Teuza VC and others.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.